Some agents targeting IL1B, such as soluble decoy IL-1 receptor, IL-1 receptor antagonist and neutralizing monoclonal antibodies against IL-1, have been approved in clinics to treat inflammatory and autoimmune diseases diseases [24, 27, 28]. The gene discussed is IL1B; the disease is autoimmune disease.